Principal component analysis of adipocytokines and insulin associate with risk factors of cardiovascular diseases.
Adipocytokines
Cardiovascular diseases
Obesity
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
29
11
2019
accepted:
25
02
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
12
1
2021
Statut:
epublish
Résumé
Obesity plays an important role in the development of chronic diseases like cardiovascular diseases and diabetes. The possible underlying mechanism for this connection is that adipose tissue secretes an array of chemical messenger adipokines proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, and interleukin-1-beta). This study aimed to investigate the linkage between adipocytokines and insulin with the cardiovascular disease risk, with particular reference to the adipokines galectin-3, plasminogen activator inhibitor-1, and interleukin-1-beta, C-reactive protein, and monocyte chemoattractant protein. Two patterns were identified. The first pattern was galectin-3, plasminogen activator inhibitor-1 and interleukin-1-beta and the second one was C-reactive protein, insulin and monocyte chemoattractant protein-1. The second pattern was strongly associated with the higher scores for resting metabolic rate, diastolic blood pressure, homeostasis model insulin resistance index, lipid profile (except low density lipoprotein, total cholesterol), and body composition parameters (except fat free mass index and waist hip ratio), while negatively associated with age and high density lipoprotein level (all p < 0.05). The first pattern was, however, significantly associated with body fat mass, obesity degree percentage, waist circumference, fat mass index, and waist hip ratio (p < 0.05 for all). This is a retrospective study. Ethics approval (IR.TUMS.VCR.REC.1395.1597).
Identifiants
pubmed: 32290863
doi: 10.1186/s13104-020-04976-9
pii: 10.1186/s13104-020-04976-9
pmc: PMC7157993
doi:
Substances chimiques
Adipokines
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Références
Cardiol Res Pract. 2011 Mar 07;2011:653182
pubmed: 21403882
JAMA. 2010 Jan 20;303(3):235-41
pubmed: 20071471
Korean J Intern Med. 2017 Mar;32(2):239-247
pubmed: 28192887
Nutr Hosp. 2010 Jul-Aug;25(4):630-4
pubmed: 20694300
J Cardiometab Syndr. 2009 Spring;4(2):113-9
pubmed: 19614799
Am J Med. 2007 Mar;120(3 Suppl 1):S3-S11
pubmed: 17320520
Curr Health Sci J. 2013 Oct;39(4):225-31
pubmed: 24778862
Curr Opin Lipidol. 2002 Aug;13(4):383-9
pubmed: 12151853
J Cardiol. 2014 Apr;63(4):250-9
pubmed: 24355497
Proc Nutr Soc. 2001 Aug;60(3):349-56
pubmed: 11681809
J Endocrinol. 2013 Jan 02;216(1):T17-36
pubmed: 23160967
J Intern Med. 2016 Jul;280(1):114-28
pubmed: 26791914
J Immunol. 2005 May 1;174(9):5789-95
pubmed: 15843582
Micron. 2006;37(3):208-22
pubmed: 16360317
J Clin Endocrinol Metab. 2002 Jun;87(6):2520-4
pubmed: 12050208
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6
pubmed: 8170963
Curr Atheroscler Rep. 2002 Nov;4(6):448-53
pubmed: 12361492
Eur Heart J. 1993 Jul;14(7):915-9
pubmed: 8375415
PLoS Med. 2004 Nov;1(2):e45
pubmed: 15578112
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1092-101
pubmed: 16039994
J Clin Endocrinol Metab. 2004 Jun;89(6):2563-8
pubmed: 15181024
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Pharmacol Ther. 2001 Feb;89(2):187-206
pubmed: 11316520
Int J Obes (Lond). 2006 Sep;30(9):1347-55
pubmed: 16534530
Nat Rev Cardiol. 2015 Nov;12(11):627-42
pubmed: 26461967
PLoS One. 2014 Jun 26;9(6):e99785
pubmed: 24968098
Thromb Haemost. 1995 Mar;73(3):374-9
pubmed: 7667818
Nutrition. 2001 Nov-Dec;17(11-12):953-66
pubmed: 11744348
J Intern Med. 2007 Oct;262(4):422-30
pubmed: 17875178
BMJ. 2001 Mar 24;322(7288):716-20
pubmed: 11264213